• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pacira Pharm Inc (NQ: PCRX )

    20.36 +0.32 (+1.62%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 832,481
    Open 19.96
    Bid (Size) 20.35 (16)
    Ask (Size) 20.36 (3)
    Prev. Close 20.03
    Today's Range 19.67 - 20.44
    52wk Range 19.34 - 40.16
    Shares Outstanding 44,454,792
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Biotech Stocks to Buy on the Dip: July 2024
    Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
    Via InvestorPlace
    Expert Ratings For Pacira BioSciences
    Via Benzinga

    Performance

    YTD
    -36.39%
    -36.39%
    1 Month
    -28.85%
    -28.85%
    3 Month
    -21.86%
    -21.86%
    6 Month
    -37.31%
    -37.31%
    1 Year
    -44.00%
    -44.00%

    More News

    Read More
    Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
    From Pacira BioSciences
    Via GlobeNewswire
    In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
    Via Chartmill
    Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
    From Pacira BioSciences
    Via GlobeNewswire
    NASDAQ:PCRX: good value for what you're paying.
    Via Chartmill
    NASDAQ:PCRX, an undervalued stock with good fundamentals.
    Via Chartmill
    Analyst Ratings For Pacira BioSciences
    Via Benzinga
    Top 5 Health Care Stocks That May Explode In July
    Via Benzinga
    This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
    Via Benzinga
    Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
    Via Benzinga
    Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
    From Pacira BioSciences
    Via GlobeNewswire
    A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
    Via Benzinga
    When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    Via Chartmill
    Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
    From Pacira BioSciences
    Via GlobeNewswire
    PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
    From Pacira BioSciences
    Via GlobeNewswire
    Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
    Via Chartmill
    Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
    Via AB Newswire
    Topics Death
    Exposures Death
    Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
    From Pacira BioSciences
    Via GlobeNewswire
    Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
    From Pacira BioSciences
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.